Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A placebo-controlled Phase 2b clinical trial combining imdusiran, interferon and NA therapy in Subjects With Chronic Hepatitis B Infection

X
Trial Profile

A placebo-controlled Phase 2b clinical trial combining imdusiran, interferon and NA therapy in Subjects With Chronic Hepatitis B Infection

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 17 Jan 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Imdusiran (Primary) ; Interferon; Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Jan 2025 New trial record
    • 13 Jan 2025 According to Arbutus Biopharma media release, company anticipates to initiate this trial in the first half of 2025.
    • 13 Jan 2025 According to Arbutus Biopharma media release, company announced that Subject to regulatory approval, the clinical trial is anticipated to enroll approximately 170 HBeAg-negative cHBV patients with baseline HBsAg less than or equalto 1000 IU/mL.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top